NCT02626884View on ClinicalTrials.gov

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
Interventions
DRUG

Ibrutinib

Trial Locations (1)

Unknown

1st Department of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT02626884 - Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) | Biotech Hunter | Biotech Hunter